EU investment institution the European Investment Bank (EIB) will provide €2-million in financing for early-stage vaccine development in Rwanda. The financing, which will be provided to Akagera Medicines Africa, will support research and development efforts for new vaccines to treat infectious diseases such as tuberculosis, human immunodeficiency virus, Lassa fever and Ebola.
